A blockbuster drug is a best-selling medication earning over $1 billion annually. Learn about them and how they revolutionize ...

Biosimilars save billions, but FDA’s new guidance, physician concerns, and Humira switchbacks reveal hurdles to a sustainable US market.

Detailed price information for Johnson & Johnson (JNJ-N) from The Globe and Mail including charting and trades.

ABBV's Skyrizi and Rinvoq drove more than 40% growth in 2025. Can these immunology blockbusters power double-digit gains again in 2026?

We are thrilled to welcome Elaine to Artiva’s board at such an important time for the company,” said Fred Aslan, M.D., president and chief executive officer of Artiva Biotherapeutics. “Elaine brings ...

AbbVie recently reported record 2025 results and outlined a stronger 2026 outlook, while advancing key immunology assets and ...

BCBS Michigan saved $67 million and $80 million in 2024 and 2025, respectively, through biosimilar use, the insurer reported Feb. 17. The company began moving members from Humira and Stelara to ...

Tuesday, February 17, 2026 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including AbbVie Inc ...

AbbVie (ABBV) is back in focus after releasing fourth quarter and full year 2025 results, alongside fresh regulatory filings for Rinvoq in vitiligo that highlight how its growth engine extends beyond ...

President Trump blared about the “GREAT JOBS NUMBERS” from last week’s jobs report. But a deeper look at the data shows the U ...

Detailed price information for Johnson & Johnson (JNJ-N) from The Globe and Mail including charting and trades.

The total net revenues of AbbVie's Rinvoq and Skyrizi were about $25.87 billion in 2025, up 46.2% from 2024. Read why ABBV ...